Tempest Therapeutics (NASDAQ:TPST) Issues Quarterly Earnings Results, Beats Expectations By $2.48 EPS

Tempest Therapeutics (NASDAQ:TPST) issued its quarterly earnings results on Wednesday. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($3.27) by $2.48, Zacks reports.

Tempest Therapeutics Stock Down 4.1%

NASDAQ TPST traded down $0.41 during trading on Thursday, hitting $9.54. 20,256 shares of the stock traded hands, compared to its average volume of 43,216. The company has a market capitalization of $42.36 million, a P/E ratio of -0.95 and a beta of -2.20. The firm has a 50-day simple moving average of $10.34 and a 200-day simple moving average of $8.43. Tempest Therapeutics has a 12-month low of $5.33 and a 12-month high of $15.08.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tempest Therapeutics presently has an average rating of “Hold” and a consensus price target of $30.00.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.